Audited standalone Financial Result for quarter and Financial year ended 31st march, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Pentokey Organy India Ltd reported FY2025-26 revenue of ₹209 lakh, a massive jump from ₹82.62 lakh in the prior year — driven by the company's pharma/pesticides trading segment. However, net profit declined to ₹20.32 lakh from ₹24.55 lakh, indicating margin compression as expenses grew proportionally with revenue. The Q4 standalone result shows a loss of ₹13.14 lakh (revenue negative ₹186.39 lakh due to nature of presentation), offset by strong performance in the first three quarters. The company maintains a healthy balance sheet with total equity of ₹969.52 lakh, cash and bank balances of over ₹604 lakh, and minimal debt. Statutory auditors Verma Mehta & Associates issued an unmodified (clean) opinion, and the auditor's report contains no qualifications, adverse opinions, or emphasis of matter. No auditor change was noted.
Revenue nearly tripled but profitability declined year-on-year, suggesting cost inefficiencies as the business scales. The strong balance sheet and clean audit opinion provide stability, but the declining PAT is a concern for shareholders expecting margin improvement with top-line growth.